Consensus for HER2 alterations testing in non-small-cell lung cancer

S. Ren, J. Wang, J. Ying, T. Mitsudomi, D. H. Lee, Z. Wang, Q. Chu, P. C. Mack, Y. Cheng, J. Duan, Y. Fan, B. Han, Z. Hui, A. Liu, J. Liu, Y. Lu, Z. Ma, M. Shi, Y. Shu, Q. SongX. Song, Y. Song, C. Wang, X. Wang, Y. Xu, Y. Yao, L. Zhang, M. Zhao, B. Zhu, J. Zhang, C. Zhou, F. R. Hirsch

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Human epidermal growth factor receptor 2 (HER2) is a transmembrane glycoprotein receptor with intracellular tyrosine kinase activity. Its alterations, including mutation, amplification and overexpression, could result in oncogenic potential and have been detected in many cancers such as non-small-cell lung cancer (NSCLC). Such alterations are, in general, considered markers of poor prognosis. Anti-HER2 antibody-drug conjugates, e.g. trastuzumab deruxtecan (T-DXd, DS-8201) and disitamab vedotin (RC48), were recently approved for HER2-positive breast and gastric cancers. Meanwhile, several HER2-targeted drugs, such as T-DXd, neratinib, afatinib, poziotinib and pyrotinib, have been evaluated in patients with advanced NSCLC, with several of them demonstrating clinical benefit. Therefore, identifying HER2 alterations is pivotal for NSCLC patients to benefit from these targeted therapies. Recent guidelines on HER2 testing were developed for breast and gastric cancer, however, and have not been fully established for NSCLC. The expert group here reached a consensus on HER2 alteration testing in NSCLC with the focus on clinicopathologic characteristics, therapies, detection methods and diagnostic criteria for HER2-altered NSCLC patients. We hope this consensus could improve the clinical management of NSCLC patients with HER2 alterations.

Original languageEnglish
Article number100395
JournalESMO Open
Issue number1
StatePublished - Feb 2022


  • amplification
  • gene testing
  • human epidermal growth factor receptor 2
  • mutation
  • non-small-cell lung cancer
  • overexpression


Dive into the research topics of 'Consensus for HER2 alterations testing in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this